Please use this identifier to cite or link to this item: https://accedacris.ulpgc.es/handle/10553/136336
DC FieldValueLanguage
dc.contributor.authorPascual-Figal, Domingoen_US
dc.contributor.authorBayés-Genis, Antonien_US
dc.contributor.authorBeltrán-Troncoso, Paolaen_US
dc.contributor.authorCaravaca-Pérez, Pedroen_US
dc.contributor.authorConde Martel, Aliciaen_US
dc.contributor.authorCrespo-Leiro, Maria G.en_US
dc.contributor.authorDelgado, Juan F.en_US
dc.contributor.authorDíez, Javieren_US
dc.contributor.authorFormiga, Francescen_US
dc.contributor.authorManito, Nicolásen_US
dc.date.accessioned2025-02-19T11:35:09Z-
dc.date.available2025-02-19T11:35:09Z-
dc.date.issued2021en_US
dc.identifier.issn2297-055Xen_US
dc.identifier.urihttps://accedacris.ulpgc.es/handle/10553/136336-
dc.description.abstractHeart failure (HF) is a clinical syndrome characterized by the presence of dyspnea or limited exertion due to impaired cardiac ventricular filling and/or blood ejection. Because of its high prevalence, it is a major health and economic burden worldwide. Several mechanisms are involved in the pathophysiology of HF. First, the renin-angiotensin-aldosterone system (RAAS) is over-activated, causing vasoconstriction, hypertension, elevated aldosterone levels and sympathetic tone, and eventually cardiac remodeling. Second, an endogenous compensatory mechanism, the natriuretic peptide (NP) system is also activated, albeit insufficiently to counteract the RAAS effects. Since NPs are degraded by the enzyme neprilysin, it was hypothesized that its inhibition could be an important therapeutic target in HF. Sacubitril/valsartan is the first of the class of dual neprilysin and angiotensin receptor inhibitors (ARNI). In patients with HFrEF, treatment with sacubitril/valsartan has demonstrated to significantly reduce mortality and the rates of hospitalization and rehospitalization for HF when compared to enalapril. This communication reviews in detail the demonstrated benefits of sacubitril/valsartan in the treatment of patients with HFrEF, including reduction of mortality and disease progression as well as improvement in cardiac remodeling and quality of life. The hemodynamic and organic effects arising from its dual mechanism of action, including the impact of neprilysin inhibition at the renal level, especially relevant in patients with type 2 diabetes mellitus, are also reviewed. Finally, the evidence on the demonstrated safety and tolerability profile of sacubitril/valsartan in the different subpopulations studied has been compiled. The review of this evidence, together with the recommendations of the latest clinical guidelines, position sacubitril/valsartan as a fundamental pillar in the treatment of patients with HFrEF.en_US
dc.languageengen_US
dc.relation.ispartofFrontiers In Cardiovascular Medicineen_US
dc.sourceFrontiers In Cardiovascular Medicine [ISSN 2297-055X], v. 8en_US
dc.subject.otherARNIen_US
dc.subject.otherHeart failureen_US
dc.subject.otherHeart failure with reduced ejection fractionen_US
dc.subject.otherNeprilysin inhibitionen_US
dc.subject.otherSacubitril/valsartanen_US
dc.titleSacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Reviewen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.identifier.doi10.3389/fcvm.2021.754499en_US
dc.identifier.scopus2-s2.0-85130724629-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.relation.volume8en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.utils.revisionen_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr1,443
dc.description.jcr5,846
dc.description.sjrqQ1
dc.description.jcrqQ2
dc.description.esciESCI
dc.description.miaricds10,3
item.fulltextCon texto completo-
item.grantfulltextopen-
crisitem.author.deptGIR IUIBS: Patología y Tecnología médica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-2540-3880-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameConde Martel, Alicia-
Appears in Collections:Artículos
Adobe PDF (2,5 MB)
Show simple item record

SCOPUSTM   
Citations

41
checked on Mar 30, 2025

WEB OF SCIENCETM
Citations

42
checked on Mar 30, 2025

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.